Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir

By Calza Leonardo   Trapani Filippo   Salvadori Caterina   Magistrelli Eleonora   Manfredi Roberto   Colangeli Vincenzo   Di Bari Maria Assunta   Borderi Marco   Viale Pierluigi  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 2, 2013-02 ,pp. : 147-154

Informa Healthcare

Access to resources Recommend Favorite

Comparison of P-Triglyceride Levels among Patients with Human Immunodeficiency Virus on Randomized Treatment with Ritonavir, Indinavir or Ritonavir/Saquinavir

By Røge Birgit T.   Katzenstein Terese L.   Gerstoft Jan  

Scandinavian Journal of Infectious Diseases, Vol. 33, Iss. 4, 2001-04 ,pp. : 306-311

Informa Healthcare

Access to resources Recommend Favorite

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

By Andersson Lars-Magnus  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 7, 2013-07 ,pp. : 543-551

Informa Healthcare

Access to resources Recommend Favorite

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

By Cohen C.   Nieto-Cisneros L.   Zala C.   Fessel W. J.   Gonzalez-Garcia J.   Gladysz A.   McGovern R.   Adler E.   McLaren C.    

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1683-1692

Informa Healthcare

Access to resources Recommend Favorite

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

By Di Biagio Antonio  

Journal of Infection and Chemotherapy, Vol. 18, Iss. 4, 2012-08 ,pp. : 587-590

Springer Publishing Company

Access to resources Recommend Favorite